- Home
- IVCA vs QNCX Comparison
IVCA vs QNCX Comparison
Compare IVCA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVCA
- QNCX
- Stock Information
- Founded
- IVCA 2021
- QNCX 2012
- Country
- IVCA Cayman Islands
- QNCX United States
- Employees
- IVCA N/A
- QNCX N/A
- Industry
- IVCA Blank Checks
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVCA Finance
- QNCX Health Care
- Exchange
- IVCA Nasdaq
- QNCX Nasdaq
- Market Cap
- IVCA 93.2M
- QNCX 92.3M
- IPO Year
- IVCA 2022
- QNCX 2019
- Fundamental
- Price
- IVCA $11.73
- QNCX $1.95
- Analyst Decision
- IVCA
- QNCX Strong Buy
- Analyst Count
- IVCA 0
- QNCX 3
- Target Price
- IVCA N/A
- QNCX $9.67
- AVG Volume (30 Days)
- IVCA 287.0
- QNCX 286.7K
- Earning Date
- IVCA 01-01-0001
- QNCX 11-13-2024
- Dividend Yield
- IVCA N/A
- QNCX N/A
- EPS Growth
- IVCA N/A
- QNCX N/A
- EPS
- IVCA 0.26
- QNCX N/A
- Revenue
- IVCA N/A
- QNCX N/A
- Revenue This Year
- IVCA N/A
- QNCX N/A
- Revenue Next Year
- IVCA N/A
- QNCX N/A
- P/E Ratio
- IVCA $45.52
- QNCX N/A
- Revenue Growth
- IVCA N/A
- QNCX N/A
- 52 Week Low
- IVCA $10.96
- QNCX $0.51
- 52 Week High
- IVCA $12.37
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- IVCA 83.33
- QNCX 52.02
- Support Level
- IVCA $11.70
- QNCX $1.80
- Resistance Level
- IVCA $11.92
- QNCX $2.09
- Average True Range (ATR)
- IVCA 0.01
- QNCX 0.21
- MACD
- IVCA -0.00
- QNCX -0.05
- Stochastic Oscillator
- IVCA 14.29
- QNCX 27.01
About IVCA Investcorp India Acquisition Corp.
Investcorp AI Acquisition Corp is a blank check company.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.